Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab with bevacizumab within its marketing authorisation for treating unresectable or advanced hepatocellular carcinoma.
 
Status In progress
Process STA 2018
ID number 1655

Provisional Schedule

Invitation to participate 04 June 2020
Committee meeting 07 October 2020
Expected publication 16 December 2020

Project Team

Project lead Gemma Barnacle

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Consultees

Companies sponsors Roche (Atezolizumab, bevacizumab)
Others Department of Health and Social Care
  NHS Nene CCG
  NHS West Suffolk CCG
  NHS England
  Welsh Government
Patient carer groups Addenbrookes Liver Transplant Association
  Black Health Agency
  British Liver Trust
  Cancer Black Care
  Cancer Equality
  Cancer 52
  Children's Liver Disease Foundation
  Chinese National Healthy Living Centre
  Helen Rollason Cancer Charity
  Hepatitis B Foundation UK
  Hepatitis C Trust
  Independent Cancer Patients’ Voice
  Liver4Life
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  Pelican Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Anaesthetists of Great Britain & Ireland
  Association of Cancer Physicians
  Association of Surgeons of Great Britain and Ireland
  British Association of the Study of the Liver
  British Geriatrics Society
  British Institute of Radiologists
  British Liver Nurses Association
  British Psychosocial Oncology Society
  British Society of Gastroenterology
  Cancer Research UK
  Hepatitis Nurse Specialist Forum
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiologists
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Bayer (sorafenib)
  Eisai (lenvatinib)
General commentators Allied Health Professionals Federation
  All Wales Therapeutics and Toxicology Centre
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Hepato-biliary Group
  Cochrane Infectious Diseases Group
  Foundation for Liver Research
  Guts UK
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
11 December 2019 - 20 January 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
02 August 2019 In progress, DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance